# Taligen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taligen-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.taligentherapeutics.com
- Total disclosed funding: $79M
- Latest round: Series B (Aug 23, 2010)
- Investors on record: 6

## About

Taligen Therapeutics is a biotechnology company focused on enhancing healthcare outcomes through innovative research and development solutions tailored for academic and pharmaceutical sectors.Founded in 2004 and headquartered in Cambridge, US, Taligen Therapeutics specializes in developing biotechnology solutions. The company was acquired by Alexion Pharmaceuticals, Inc. in January 2011 for USD 111 mn. Over its operational years, Taligen has engaged in 5 total deals.Taligen Therapeutics specializes in providing innovative biotechnology solutions aimed at enhancing patient outcomes through advanced research and development. The company's core product offerings include comprehensive research modules tailored for teams of various sizes, enabling users to conduct basic and advanced biotechnology projects. Taligen’s services support researchers in developing groundbreaking therapies by facilitating quick onboarding and ensuring a high level of user satisfaction. Targeting markets primarily in North America and Europe, Taligen serves a diverse client base, including academic institutions, pharmaceutical companies, and research organizations addressing critical healthcare challenges.Taligen Therapeutics operates on a subscription-based revenue model with tiered pricing plans that cater to different customer needs. The company’s pricing structure comprises three main service levels: Beginner at USD 35 per month for basic research and development tools; Expertise at USD 65 per month for comprehensive solutions including access to all research modules; and Expert at USD 125 per month for full access to all resources and 24/7 support. Transactions typically occur directly between Taligen and its clients, with customers subscribing to the service plans that best meet their research requirements, allowing Taligen to maintain a steady revenue stream while delivering tailored solutions.Taligen Therapeutics plans to leverage its recent acquisition by Alexion Pharmaceuticals to expand its research capabilities and introduce new product offerings that enhance therapeutic development. While specific details on upcoming product launches have yet to be disclosed, the company aims to broaden its market presence in Europe and North America by 2025. The funding obtained from the acquisition will be utilized to support these initiatives and enhance the company's research and development infrastructure.

## Funding rounds

- Series B, Aug 23, 2010, $10M — Alta Partners, Sanderling Ventures, Clarus Ventures, High Country Venture
- Series B, Feb 1, 2008, $65M — Alta Partners, Sanderling Ventures, Clarus Ventures, High Country Venture
- Series A, Sep 1, 2006 — Sanderling Ventures, Tangoe, Inc., High Country Venture, University License Equity Holdings
- Series A, Aug 1, 2005, $3.8M — Sanderling Ventures, Tangoe, Inc., High Country Venture, University License Equity Holdings

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A, Series B
- Tangoe, Inc. — Series A
- High Country Venture (https://capitalatlas.ai/funds/high-country-venture) — Series A, Series B
- University License Equity Holdings — Series A
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B